Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Deciphering miRNA signatures in axial spondyloarthritis: The link between miRNA-1-3p and pro-inflammatory cytokines

A. Prokopcova, J. Baloun, K. Bubova, M. Gregova, S. Forejtova, J. Horinkova, M. Husakova, K. Mintalova, V. Cervenak, M. Tomcik, J. Vencovsky, K. Pavelka, L. Senolt

. 2024 ; 10 (19) : e38250. [pub] 20240921

Status not-indexed Language English Country England, Great Britain

Document type Journal Article

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that affects the spine and sacroiliac joints. Early detection of axSpA is crucial to slow disease progression and maintain remission or low disease activity. However, current biomarkers are insufficient for diagnosing axSpA or distinguishing between its radiographic (r-axSpA) and non-radiographic (nr-axSpA) subsets. To address this, we conducted a study using miRNA profiling with massive parallel sequencing (MPS) and SmartChip qRT-PCR validation. The goal was to identify differentially expressed miRNAs in axSpA patients, specifically those subdiagnosed with nr-axSpA or r-axSpA. Disease activity was measured using C-reactive protein (CRP) and the Ankylosing Spondylitis Disease Activity Score (ASDAS). Radiographic assessments of the cervical and lumbar spine were performed at baseline and after two years. Out of the initial 432 miRNAs, 90 met the selection criteria, and 45 were validated out of which miR-1-3p was upregulated, whereas miR-1248 and miR-1246 were downregulated in axSpA patients. The expression of miR-1-3p correlated with interleukin (IL)-17 and tumour necrosis factor (TNF) levels, indicating its significant role in axSpA pathogenesis. Although specific miRNAs distinguishing disease subtypes or correlating with disease activity or spinal changes were not found, the study identified three dysregulated miRNAs in axSpA patients, with miR-1-3p linked to IL-17 and TNF, underscoring its pathogenetic significance. These findings could help improve the early detection and treatment of axSpA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002360
003      
CZ-PrNML
005      
20250910082153.0
007      
ta
008      
250117s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.heliyon.2024.e38250 $2 doi
035    __
$a (PubMed)39398012
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Prokopcová, Aneta $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08, Prague, Czech Republic $7 xx0283004
245    10
$a Deciphering miRNA signatures in axial spondyloarthritis: The link between miRNA-1-3p and pro-inflammatory cytokines / $c A. Prokopcova, J. Baloun, K. Bubova, M. Gregova, S. Forejtova, J. Horinkova, M. Husakova, K. Mintalova, V. Cervenak, M. Tomcik, J. Vencovsky, K. Pavelka, L. Senolt
520    9_
$a Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that affects the spine and sacroiliac joints. Early detection of axSpA is crucial to slow disease progression and maintain remission or low disease activity. However, current biomarkers are insufficient for diagnosing axSpA or distinguishing between its radiographic (r-axSpA) and non-radiographic (nr-axSpA) subsets. To address this, we conducted a study using miRNA profiling with massive parallel sequencing (MPS) and SmartChip qRT-PCR validation. The goal was to identify differentially expressed miRNAs in axSpA patients, specifically those subdiagnosed with nr-axSpA or r-axSpA. Disease activity was measured using C-reactive protein (CRP) and the Ankylosing Spondylitis Disease Activity Score (ASDAS). Radiographic assessments of the cervical and lumbar spine were performed at baseline and after two years. Out of the initial 432 miRNAs, 90 met the selection criteria, and 45 were validated out of which miR-1-3p was upregulated, whereas miR-1248 and miR-1246 were downregulated in axSpA patients. The expression of miR-1-3p correlated with interleukin (IL)-17 and tumour necrosis factor (TNF) levels, indicating its significant role in axSpA pathogenesis. Although specific miRNAs distinguishing disease subtypes or correlating with disease activity or spinal changes were not found, the study identified three dysregulated miRNAs in axSpA patients, with miR-1-3p linked to IL-17 and TNF, underscoring its pathogenetic significance. These findings could help improve the early detection and treatment of axSpA.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Baloun, Jiri $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic
700    1_
$a Bubova, Kristyna $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08, Prague, Czech Republic
700    1_
$a Gregova, Monika $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic
700    1_
$a Forejtova, Sarka $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08, Prague, Czech Republic
700    1_
$a Horinkova, Jana $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08, Prague, Czech Republic
700    1_
$a Husakova, Marketa $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08, Prague, Czech Republic
700    1_
$a Mintalova, Katerina $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic
700    1_
$a Cervenak, Vladimir $u Department of Medical Imaging, St Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekarska 664/53, 602 00, Brno, Czech Republic
700    1_
$a Tomcik, Michal $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08, Prague, Czech Republic
700    1_
$a Vencovsky, Jiri $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08, Prague, Czech Republic
700    1_
$a Pavelka, Karel $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08, Prague, Czech Republic
700    1_
$a Senolt, Ladislav $u Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08, Prague, Czech Republic
773    0_
$w MED00190064 $t Heliyon $x 2405-8440 $g Roč. 10, č. 19 (2024), s. e38250
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39398012 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250910082138 $b ABA008
999    __
$a ok $b bmc $g 2254552 $s 1238363
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 10 $c 19 $d e38250 $e 20240921 $i 2405-8440 $m Heliyon $n Heliyon $x MED00190064
LZP    __
$a Pubmed-20250117

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...